Oral Bisphosphonate Use Cuts Risk of Post-Implant Revision Sx

This article originally appeared here.
Share this content:
Oral Bisphosphonate Use Cuts Risk of Post-Implant Revision Sx
Oral Bisphosphonate Use Cuts Risk of Post-Implant Revision Sx

(HealthDay News) -- For patients undergoing total joint replacement, oral bisphosphonate use is associated with a reduction in the risk of revision surgery, according to a study published in the November issue of Arthritis & Rheumatology.

Daniel Prieto-Alhambra, M.D., Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a retrospective cohort study within Danish nationwide registries to examine the correlation between bisphosphonate use and implant survival. Patients aged 40 years or older undergoing total joint replacement between 1998 and 2007 were identified. Each of 1,558 bisphosphonate users was matched, using propensity scores, to up to six bisphosphonate nonusers (n = 8,966).

The researchers found that during the follow-up period, 1.73 percent of bisphosphonate users and 4.45 percent of matched nonusers underwent revision surgery, at a median of 2.61 years after first surgery. Bisphosphonate users had a reduced risk of revision surgery (hazard ratio, 0.41). Patients with the longest duration of treatment and/or the best adherence had the strongest correlation.

"Oral bisphosphonate users have a 59 percent reduced risk of revision surgery," the authors write. "This association is only present when bisphosphonates are started after arthroplasty surgery."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths